Last reviewed · How we verify
IBI343,sintilimab,oxaliplatin,S-1
IBI343,sintilimab,oxaliplatin,S-1 is a PD-1/PD-L1 inhibitor Small molecule drug developed by Innovent Biologics (Suzhou) Co. Ltd.. It is currently in Phase 2 development for Non-small cell lung cancer, Colorectal cancer.
Programmed death-ligand 1 inhibitor
Programmed death-ligand 1 inhibitor Used for Non-small cell lung cancer, Colorectal cancer.
At a glance
| Generic name | IBI343,sintilimab,oxaliplatin,S-1 |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Sintilimab is a monoclonal antibody that binds to programmed death-ligand 1 (PD-L1), preventing its interaction with programmed death-1 (PD-1) on T cells, thereby enhancing T cell-mediated immune response against cancer cells.
Approved indications
- Non-small cell lung cancer
- Colorectal cancer
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE2)
- IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI343,sintilimab,oxaliplatin,S-1 CI brief — competitive landscape report
- IBI343,sintilimab,oxaliplatin,S-1 updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI
Frequently asked questions about IBI343,sintilimab,oxaliplatin,S-1
What is IBI343,sintilimab,oxaliplatin,S-1?
How does IBI343,sintilimab,oxaliplatin,S-1 work?
What is IBI343,sintilimab,oxaliplatin,S-1 used for?
Who makes IBI343,sintilimab,oxaliplatin,S-1?
What drug class is IBI343,sintilimab,oxaliplatin,S-1 in?
What development phase is IBI343,sintilimab,oxaliplatin,S-1 in?
What are the side effects of IBI343,sintilimab,oxaliplatin,S-1?
What does IBI343,sintilimab,oxaliplatin,S-1 target?
Related
- Drug class: All PD-1/PD-L1 inhibitor drugs
- Target: All drugs targeting PD-L1
- Manufacturer: Innovent Biologics (Suzhou) Co. Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Colorectal cancer
- Compare: IBI343,sintilimab,oxaliplatin,S-1 vs similar drugs
- Pricing: IBI343,sintilimab,oxaliplatin,S-1 cost, discount & access